Cargando…

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

SIMPLE SUMMARY: One of the most frequently diagnosed cancer in men is adenocarcinoma of the prostate. Once the disease is metastatic, only very limited treatment options are available, resulting in a very short median survival time of 13 months; however, this reality is gradually changing due to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Fakiri, Mohamed, Geis, Nicolas M., Ayada, Nawal, Eder, Matthias, Eder, Ann-Christin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393521/ https://www.ncbi.nlm.nih.gov/pubmed/34439121 http://dx.doi.org/10.3390/cancers13163967

Ejemplares similares

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
por: Arbuznikova, Daria, et al.
Publicado: (2023)

The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
por: Eder, Ann-Christin, et al.
Publicado: (2021)

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
por: Eder, Ann-Christin, et al.
Publicado: (2022)

[(177)Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography
por: Tönnesmann, Roswitha, et al.
Publicado: (2019)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2022)

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach
por: Lahnif, Hanane, et al.
Publicado: (2021)

Current status and future perspective of radiopharmaceuticals in China
por: Hu, Ji, et al.
Publicado: (2021)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
por: Ruigrok, Eline A.M., et al.
Publicado: (2019)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

Highlights of the Latest Developments in Radiopharmaceuticals for Infection Imaging and Future Perspectives
por: Dadachova, Ekaterina, et al.
Publicado: (2022)

The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review
por: Rizzo, Alessio, et al.
Publicado: (2023)

Cold Kit Labeling: The Future of (68)Ga Radiopharmaceuticals?
por: Lepareur, Nicolas
Publicado: (2022)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [(18)F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model
por: Kim, Su Bin, et al.
Publicado: (2022)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [(177)Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial
por: Shin, Dongho, et al.
Publicado: (2022)

Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [(68)Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice
por: Kim, Su Bin, et al.
Publicado: (2021)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Clinical perspectives of PSMA PET/MRI for prostate cancer
por: Barbosa, Felipe de Galiza, et al.
Publicado: (2018)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
por: Flores, Orielyz, et al.
Publicado: (2017)

PSMA-targeted therapy for non-prostate cancers
por: Wang, Jarey H., et al.
Publicado: (2023)

Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
por: Rizzo, Alessio, et al.
Publicado: (2022)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
por: Ng, Thomas S. C., et al.
Publicado: (2021)

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective
por: Ricci, Maria, et al.
Publicado: (2021)

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
por: Wüstemann, Till, et al.
Publicado: (2016)

Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium‐177 prostate‐specific membrane antigen (PSMA) therapy
por: Zoberi, Jacqueline E., et al.
Publicado: (2023)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer
por: Meher, Niranjan, et al.
Publicado: (2023)

PET Oncological Radiopharmaceuticals: Current Status and Perspectives
por: Lin, Mai, et al.
Publicado: (2022)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer
por: Shen, Colette J., et al.
Publicado: (2020)

Stroma Targeting Nuclear Imaging and Radiopharmaceuticals
por: Shetty, Dinesh, et al.
Publicado: (2012)

Recent advances and future perspectives in the therapeutics of prostate cancer
por: Varaprasad, Ganji Lakshmi, et al.
Publicado: (2023)

Radiopharmaceuticals in Nuclear Medicine: Recent Developments for SPECT and PET Studies
por: Gutfilen, Bianca, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pkmksm5iq2qi37bn5t5upavcjh